Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment.
about
Cytomegalovirus Hyper Immunoglobulin for CMV Prophylaxis in Thoracic TransplantationLetermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirusClinical utility of viral load in management of cytomegalovirus infection after solid organ transplantationFully automated quantification of cytomegalovirus (CMV) in whole blood with the new sensitive Abbott RealTime CMV assay in the era of the CMV international standardPerivascular stromal cells as a potential reservoir of human cytomegalovirus.Cytomegalovirus impairs the induction of indoleamine 2,3-dioxygenase mediated antimicrobial and immunoregulatory effects in human fibroblasts.Induction of cytomegalovirus-specific T cell responses in healthy volunteers and allogeneic stem cell recipients using vaccination with messenger RNA-transfected dendritic cells.Assessing assay agreement estimation for multiple left-censored data: a multiple imputation approach.The Cellular Localization of Human Cytomegalovirus Glycoprotein Expression Greatly Influences the Frequency and Functional Phenotype of Specific CD4+ T Cell Responses.Brincidofovir Use after Foscarnet Crystal Nephropathy in a Kidney Transplant Recipient with Multiresistant Cytomegalovirus Infection.Viral infection causes a shift in the self peptide repertoire presented by human MHC class I molecules.Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine.New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients.Prevention of cytomegalovirus following solid organ transplantation: a literature review.Immune-based monitoring for cytomegalovirus infection in solid organ transplantation: is it ready for clinical primetime?Cytomegalovirus infection in liver transplant recipients: updates on clinical managementKDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors.Cytomegalovirus Infection in Pediatric Solid Organ Transplant Recipients: a Focus on Prevention.In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication.Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment.Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment.Treatment of Cytomegalovirus Infection with Cidofovir and CMV Immune Globulin in a Lung Transplant Recipient.In vitro evaluation of cytomegalovirus-specific hyperimmune globulins vs. standard intravenous immunoglobulins.Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.Cytomegalovirus disease in patients with common variable immunodeficiency: three case reports.Human cytomegalovirus vaccine development: Immune responses to look into vaccine strategy.Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects.
P2860
Q26768477-31312871-084A-4DC6-9A45-EDA49A556A90Q26783282-49861E9E-2BF4-414E-A295-877B26B4B55DQ26826856-1CC988ED-8071-4641-85B2-190BA2EE5F99Q28680756-B9A7C9AD-2AD2-4359-A480-9CE10E40EF98Q33714313-26FD9EF0-62E3-4F9C-A223-FE248883E05AQ34731636-3388F53F-57A4-40EE-97B6-131A60FBB496Q34796892-CC6529B1-E43B-4B8F-B1B1-5DB31135A079Q35310570-6F24083D-1451-4125-B694-54978FB64F78Q36116754-8013B732-7871-46B1-901A-E576DF360AA5Q36324846-BC6BEAE4-A6EC-4CEB-A5F1-0543A5F8ABE3Q37035972-8905FC27-4C24-45F0-AABD-3389C341138BQ37409489-9C3589C6-9EB2-4AF5-9F00-C4D879F109ACQ37432614-EC837213-8939-4DD5-90E7-6D4A9F08FA00Q38124439-8DE2D08E-744B-4B73-83C4-A24F5CB079B6Q38235723-5F9458FD-8C89-44F7-A0A1-C53A4E3F79A9Q38242802-1198921D-E28E-470C-80B2-5B53ADC3FF69Q38652031-34724BEF-03BE-4113-8AD3-5CC7536FC570Q38689823-D281A1EB-64EB-48FB-A809-201F88559356Q38898723-888E7CC5-48A8-48D0-9D28-6E6A819FF04BQ40117235-F7EDCF4D-CE22-4A9A-B47A-4379DB3AB8F0Q40272806-5161246C-E06E-40D6-B3C4-E0EC9C546B1AQ40788353-3876F85A-2D3A-4BD1-A092-B9D6D07D577BQ41233197-60CB0DF7-C10F-436E-89D4-79C57124F056Q41496012-47919D14-6AE5-4F8F-9D64-55E71C53DFF6Q42254755-4AB0DE9B-77E6-4C64-9D44-96A0E575EFB3Q47605886-2F1294C9-CFD4-49E3-8801-7723705E50B7Q53807644-05FEAEBA-2705-41E2-8772-32767A8D806A
P2860
Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment.
@en
type
label
Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment.
@en
prefLabel
Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment.
@en
P2860
P1476
Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment.
@en
P2093
Raymund R Razonable
P2860
P304
P356
10.1007/S11908-012-0292-2
P50
P577
2012-12-01T00:00:00Z